

AUSTRALIAN AND NEW ZEALAND MYELOMA AND RELATED DISEASES REGISTRY (ANZ MRDR)

2024 ANNUAL REPORT





The MRDR is a clinical registry established in 2012 that aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

The registry has participating hospitals and clinics in all jurisdictions in Australia and New Zealand. Data collected includes patient demographics, clinical characteristics, test results at diagnosis, treatment, response, follow-up and outcomes including survival and quality of life.

BENCHMARKING TO IMPROVE CARE

The MRDR provides six-monthly data reports to participating sites comparing each site's registry data to the rest of the MRDR cohort. Treatment varies between centres, and these reports allow treating institutes and clinicians to identify areas of difference where there may be opportunities for improvement. In this way the MRDR facilitates work towards higher quality care.

MRDR NETWORK

The established MRDR network and data collection infrastructure of >50 participating metropolitan & regional, public & private health services throughout Australia and New Zealand provides a solid base from which to conduct many and diverse projects, and enhances our capacity for rapid translation of results. In addition, the MRDR's close association with relevant professional and research groups, Myeloma Australia (a national patient advocacy group), policy-makers and industry partners, further strengthens our capacity for research translation.

The MRDR informs national and international policy, guidelines and practice through representation of Management and Steering committee members in professional groups, as well as partner involvement:



- Haematology Society of ANZ (HSANZ)
- Haematology Society of ANZ Nursing Group (HSANZ NG)
- Myeloma Special Practice Network (M-SPN) of the HSANZ NG
- Cancer Nurses Society of Australia (CNSA)
- Myeloma Australia
- Myeloma Australia Medical Scientific Advisory Group (MSAG)
- International Myeloma Working Group (IMWG)
- Myeloma Research Group, Monash University (MRG)
- Australasian Leukaemia & Lymphoma Group (ALLG)
- Australasian Myeloma Research Consortium (AMaRC)
- Centre for Health Economics, Monash University (CHE)
- Synergistic relationship with pharmaceutical industry partners

MRDR 2024 AT A GLANCE





7927 PATIENTS REGISTERED 1176 NEW PATIENTS

74% MULTIPLE MYELOMA (MM)
24% MGUS / SMOULDERING MM¹
2% PCL² / PLASMACYTOMA



M1000 BIOBANK PATIENTS: THE ONLY PROSPECTIVE FULLY ANNOTATED 'LIQUID BIOPSY' BIOBANK IN THE WORLD

725 M1000 BIOBANK PATIENTS:



16 MYELOMA 1000 APPROVED SITES



44 REQUESTS: DATA / ANALYSES / REPORTS



 23 INVESTIGATOR-DRIVEN
15 OPERATIONAL / ONGOING REPORTS
6 INDUSTRY



MULTIPLE MYELOMA

PATIENTS

AGE (MEDIAN): 68 YEARS FEMALE 38% / MALE 62%

SURVIVAL

57% OF PATIENTS SURVIVE TO 5 YEARS

STEM CELL TRANSPLANTS IN PATIENTS WITH THE FOLLOWING AGE AT DIAGNOSIS:⁴ >70 YEARS: 10% <70 YEARS: 76% 65-70 YEARS: 65%

<65 YEARS: 81%</pre>

1. Possible precursor disease for MM

2. PCL = Plasma cell leukemia

3. Ethics approval and local governance authorisation obtained

4. Patients at least 1 year post-diagnosis with some post-registration follow-up.

MRDR RESEARCH HIGHLIGHTS FOR 2024

EpiMAP Myeloma: Epidemiological modelling to deliver better care for Australian patients with myeloma

Project Funding:

Medical Research Future Fund (MRFF) – Targeted Health System and Community Organisation Research

Chief investigators:

Zoe McQuilten, Dennis Petrie, Andrew Spencer, Erica Wood, Anthony Harris, Laura Fanning

The project developed and validated a novel patientlevel discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. The model will be used to estimate the future cost of chemotherapy in Australia and to perform cost-effectiveness analyses by comparing disease outcomes, associated quality of life, and healthcare costs between different treatment strategies. The model uses real world data from the MRDR to determine disease trajectories and outcomes. Administrative hospital data are used to determine healthcare resource use. The model will be available to inform health-care policy and service delivery planning, including decisionmaking for future funding of high-cost MM therapies.



VALUE-Ig: Evidence synthesis to inform the optimal use of immunoglobulin

Project Funding:

MRFF - Optimising the Clinical Use of Immunoglobulins

Chief investigators:

Dennis Petrie, Zoe McQuilten, Anthony Harris, Erica Wood, Adam Irving, Anneke van der Walt, Stephen Reddel, Laura Fanning, Andrew Spencer, Eliza Hawkes, Philip Crispin, Stephen Opat, Katherine Buzzard.

Immunoglobulin is a costly blood product made from human plasma. Its use in Australia is rapidly increasing despite limited evidence to inform clinical practice. The aim of VALUE-Ig is to improve the evidence base for cost-effective use of immunoglobulin. The VALUE-Ig project will complement clinical trial programs by collating observational data on immunoglobulin use, including data collected through Australian registries, and routine hospital administrative data. Clinical expert and consumer panels will validate the evidence, and preference surveys from clinicians and patients will help understand the drivers of immunoglobulin use. These data will inform economic models to understand when immunoglobulin use is cost-effective compared to alternative treatments.



ZEPFHR MM trial: A Centralized Platform for Functional High Risk Multiple Myeloma

Project Funding:

MRFF - Clinical Trials Activity

Chief investigators:

Andrew Spencer, P Joy Ho, Hang Quach, Geoffrey Hill, Roger Reddel, Nicholas Bingham, John Reynolds, Sridurga Mithraprabhu, Wee Joo Chng, Wendy Erber, Sueh-Li Lim, Christian Bryant.

Approximately 20% of MM patients in the ANZ MRDR develop relapsed MM within 12 months of diagnosis. These functional high-risk (FHR) MM patients do not respond to available treatments and have a median overall survival of <20 months. Circulating tumour DNA sequencing by the research team has shed light on the driver mutations associated with this FHR disease.

The project will create a platform to evaluate novel therapies for FHR MM, and conduct studies to better understand its biology. The platform will leverage the MRDR and AMaRC trial network; use a novel statistical design allowing early views of patients' response to therapy to decide futility or 'treatment of interest'; and, enable new treatment combinations to be launched within the trial without the usual delays.



MY-PROMPT-2: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures

Project Funding:

MRFF - Rare Cancers, Rare Diseases and Unmet Needs

Chief investigators:

Andrew Spencer, Claudia Rutherford, John Reynolds, P Joy Ho, Zoe McQuilten, Elizabeth Moore, Tracy King, Erica Wood, Simon Harrison, Adam Irving.

The MY-PROMPT-2 trial will test whether real-time symptom feedback to clinicians improves duration on therapy in patients with relapsed MM receiving standard care. MM treatment is complex and costly, however survival benefits seen in clinical trials are often not reflected in clinical practice, partly because many patients stop therapy early due to side-effects, reducing the survival benefit of optimal therapy duration. If clinicians are aware of emerging symptoms, leading to timely intervention, duration on therapy could be optimised, resulting in more efficient use of these high-cost therapies, and better patient outcomes. The MRDR encourages and supports researchers in developing and pursuing their question of interest.

FRAIL-M: Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma

Project Funding:

MRFF - Low Survival Cancers and Diseases

Chief investigators:

Andrew Spencer, Zoe McQuilten, Hang Quach, Peter Mollee, Erica Wood, John Reynolds, Ruth Hubbard, Richard De Abreu Lourenco.

The FRAIL-M trial will identify which competing treatment options are more appropriate in transplantineligible myeloma patients according to frailty status. Adapting certain standard treatment regimens according to frailty assessment in this patient group is recommended in Australian guidelines, however it had not been tested in a clinical trial, nor had the two most common treatment options been compared. Findings from this study will address these gaps, and provide a robust framework for optimisation of treatment in transplant-ineligible myeloma patients.

The trial will inform more cost-effective use of publicly funded high-cost front-line anti-MM therapies such as bortezomib and lenalidomide. FRAIL-M is recruiting in both Australia and New Zealand

The trial is open for recruitment at approved, activated sites.





MRDR COLLABORATIONS



Asia-Pacific (APAC) MRDR

The APAC MRDR is a sister registry to the MRDR in the Asia-Pacific region, and collects the same data to facilitate comparisons between countries. APAC MRDR currently has 25 hospitals enrolling participants in Korea, Malaysia, Singapore, Taiwan and China. With over 2500 patients currently on the registry there is great interest in this region, and with the data maturing, collaborations with the ANZ MRDR in several analyses have commenced, and are anticipated with other research groups.

apacmrdr.org

AMaRC: The Australasian Myeloma Research Consortium



AMaRC is a not-for-profit myeloma clinical trial research group composed of clinicians and scientists who develop and conduct investigator-led early phase and proof-of-concept studies, trialing novel drug and biologic products in Australia and New Zealand. AMaRC have valued partnerships with the pharmaceutical industry, the Myeloma Research Group laboratory, the Australasian Leukaemia & Lymphoma Group (ALLG), and Myeloma Australia. In some studies, AMaRC leverages the MRDR's established infrastructure and national site network as a platform for MM trials.

amarconline.org



Myeloma Australia

Myeloma Australia (MA) is the only myeloma-specific patient advocacy group in Australia. They support, educate, inform, and empower people living with MM, and their loved ones. Myeloma Australia is advocating for significant improvements in the availability of MM treatments in Australia and is driving the scientific conversation towards cure. The MRDR and MA work closely together, including through representation on the MRDR Steering Committee, support of and strong MRDR presence at the National Myeloma Workshop hosted by MA, funding support, and collaboration on grant applications and research projects. Numerous MRDR Steering Committee members and Principal Investigators form part of MA's Medical and Scientific Advisory Group – the peak body convened to collaborate and facilitate advances and medical care for MM in Australia.

myeloma.org.au

ANZ & APAC MRDR: COMBINED DATA SNAPSHOT

Analyses using combined ANZ and APAC MRDR data have been completed for several data requests (Presentations page 10) showing regional variation and the potential for this collaboration. In table 2 and 3 we provide a snapshot of the combined MRDR data by location from 1 January 2018 to 9 January 2025.

Table 1. Current site accrual

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
ACTIVE HOSPITALS	84	49	10	12	3	6	2	2

Table 2. Age in years at diagnosis and gender for patients with multiple myeloma (MM)

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
Ν	7606	4426	1331	1063	185	201	38	362
AGE, MEDIAN (IQR)^	67 (60, 75)	68 (60, 76)	70 (61, 77)	65 (58, 72)	67 (60, 72)	64 (57, 70)	66 (57, 72)	65 (57, 72)
AGE >70 YEARS^	41%	43%	48%	29%	36%	24%	32%	34%
GENDER (MALE)	60%	62%	58%	56%	57%	58%	63%	59%

Table 3. Most common MM chemotherapy regimens and patients who received an ASCT

	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN	CHINA
MOST COMMON 1L	VRd (53%)	VCd (82%)	VTd (39%)	VRd (34%)	VTd (40%)	VRd (40%)	VRd (38%)
MOST COMMON 1L, NO ASCT	VRd (55%)	VCd (88%)	MPV (34%)	VCd (26%)	VTd (53%)	VRd (78%)	VRd (46%)
MOST COMMON 2L	DVd (42%)	VTd (21%)	KRd (32%)	VRd (13%)	Rd (31%)	VTd, VRd (27%)	VRd, VRdD (12%)
RECEIVED ASCT*	49%	37%	57%	44%	38%	25%	49%
- AGE <70 YEARS receiving ASCT*^	76%	64%	79%	67%	48%	50%	68%
- AGE >70 YEARS*^ receiving ASCT*^	10%	3.4%	1%	8%	0%	0%	0%

1L: first-line therapy, 2L: second-line therapy, ASCT: Autologous stem cell transplant.

* Only patients with at least 1-year post-diagnosis and with some follow-up data post-registration were included.

Age: at Diagnosis; for Singapore, Date of Birth unknown-age estimated using 01 July "Year of Birth". N/A: not available/insufficient data.

Chemotherapy Codes

CODE	CHEMOTHERAPY REGIMEN
DVd	daratumumab, bortezomib, dexamethasone
KRd	carfilzomib, lenalidomide, dexamethasone
MPV	melphalan, prednisolone, bortezomib
Rd	lenalidomide, dexamethasone
VCd	bortezomib, cyclophosphamide, dexamethasone
VRd	bortezomib, lenalidomide, dexamethasone
VRdD	bortezomib, lenalidomide, dexamethasone, daratumumab
VTd	bortezomib, thalidomide, dexamethasone

MRDR PEER-REVIEWED PUBLICATIONS TO DATE

Presence of 1q21 gain and amplification may be associated with poorer outcomes in daratumumabtreated multiple myeloma

Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H. Patients. Clin Lymphoma Myeloma Leuk. 2024 Nov 9:S2152-2650(24)02402-9. doi: 10.1016/j. clml.2024.11.002.

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal. pone.0308812

The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)

Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, Spencer A. Br J Haematol. 2024 Jul 4. doi: 10.1111/bjh.19624

Variation in immunoglobulin use and impact on survival in myeloma

Chai, KL, Wellard C, LeTP T, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim KH, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso ACY, Wong KSQ, Yoon SS, Spencer A, Wood EM, McQuilten ZK. EJHaem. 2024 May;1-8 doi: 10.1002/jha2.938

Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry

Lim SL, Wellard C, Moore E, Harrison SJ, Hang Q, Ho J, Rajagopal R, Spencer A. Intern Med J. 2023 Dec 27. doi: 10.1111/imj.16277

The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)

Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglinas N, Low MS, Routledge D, Lim AB, Gibbs, SD, Quach H, Morgan S, Moore E and Ninkovic S. EJHaem. 2023 Jul;4(3): e639-e646. doi:10.1002/jha2.742

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho, Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spencer; Myeloma and Related Diseases Registry Investigators. Br J Haematol. 2023 Jan;200(2):e17-e21. https://doi. org/10.1111/bjh.18536

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Zoe McQuilten, Cameron Wellard, Elizabeth Moore, Bradley Augustson, Krystal Bergin, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer; Australian and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/ bjh.18324

Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Elizabeth Moore, Hilary Blacklock, Cameron Wellard, Ruth Spearing, Luke Merriman, Sarah Poplar, Anup George, Bart Baker, Henry Chan, Zoe McQuilten, Erica Wood, Andrew Spencer on behalf of the MRDR investigators. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8): e762-e769. doi: 10.1016/j.clml.2022.04.004

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplantineligible patients with myeloma who are treated with bortezomib-based induction.

Stephen Boyle, Cameron Wellard, Elizabeth Moore, Hilary Blacklock, Simon Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer, Peter Mollee, Myeloma and Related Diseases Registry investigators. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ ejh.13677u

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).

Krystal Bergin, Cameron Wellard, Bradley Augustson, Rachel Cooke, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Elizabeth Moore, Zoe McQuilten, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8

The myeloma landscape in Australia and New Zealand: the first eight years of the Myeloma and Related Diseases Registry (MRDR).

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Bradley Augustson, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520. doi: 10.1016/j.clml.2021.01.01

Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.

Elizabeth Moore, Tracy King, Erica Wood, Rasa Ruseckaite, Daniela Klarica, Andrew Spencer, P Joy Ho, Hang Quach, Miles Prince, Zoe McQuilten. Am J Hematol. 2020 Jul;95(7):E178-E181. doi: 10.1002/ajh.25815 Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry.

P Joy Ho, Elizabeth Moore, Zoe McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010

Myeloma in the Real World: what is really happening?

Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.e1. doi: 10.1016/j. clml.2016.12.002

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.

Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Erica Wood, Bradley Augustson, Hilary Blacklock, P Joy Ho, Noemi Horvath, Tracy King, John McNeil, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Andrew Spencer. BMC Med Res Methodol. 2016 Nov 9;16(1):151. doi: 10.1186/ s12874-016-0250-z

MRDR PRESENTATIONS 2024

ACTA Clinical Trials and Registries Symposium Australian Clinical Trials Alliance December 2024, Melbourne

Supporting real world research in myeloma: the 'data spine' of the Australian and New Zealand Myeloma and Related Diseases Registry (Oral)

Elizabeth Moore, Erica Wood, Zoe McQuilten, Adam Irving, Cameron Wellard, Andrew Spencer

American Society of Haematology (ASH) Annual Meeting December 2024, San Diego

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand: Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry Analysis (Poster)

Betty Gration, Cameron Wellard, Elizabeth Moore, Marianne Tan, Michael Murphy, Kenneth JC Lim, James Rowland, Nada Hamad, Rajeev Rajagopal, Peter Mollee, Andrew Spencer, Hang Quach, Georgia McCaughan

Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma:

Betty Gration, Cameron Wellard, Eliizabeth Moore, Peter Mollee, Ian Kerridge, Andrew Spencer, Anita Shetty, Bart Baker, Cecily Forsyth, Jessica Heenan, Zoe McQuilten, Erica Wood, Georgia McCaughan on behalf of the ANZ MRDR investigators

Integrating chromosomal 1 abnormalities into the definition of high-risk multiple myeloma: a report from the Australian & New Zealand Myeloma & Related Diseases Registries (Poster)

Kenneth JC Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jessica Zhang, Nicole Wongdoo, Sabine Ringkowski, Adam Bryant, Georgia McCaughan, Slavisa Ninkovic, Nada Hamad, Shaji K Kumar, Andrew Spencer, Hang Quach on behalf of the ANZ MRDR investigators

HSANZ Nurses Group, VIC Branch Education Dinner November 2024, Melbourne

More efficient delivery of high-cost standard-ofcare therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial (Oral)

Elizabeth Moore, Claudia Rutherford, John Reynolds, P Joy Ho, Zoe McQuilten, Elizabeth Moore, Tracy King, Erica Wood, Simon Harrison, Adam Irving, Andrew Spencer

Blood October 2024, Brisbane MRDR Annual Breakfast Meeting (hybrid)

Real world myeloma in ANZ & Asia Pacific: registry progress and latest data

A Spencer et al.

The Impact of socioeconomic status on ASCT utilisation and overall survival in myeloma in ANZ B Gration et al.

Metabolic syndrome in multiple myeloma: an analysis from the ANZ MRDR

S Ringkowski et al.

Myeloma 1000 Biobank: Powering two MRFF-funded projects

A Spencer et al.

Presentations

Functional High-Risk Multiple Myeloma following Lenalidomide-Bortezomib-dexamethasone (RVd) induction or bortezomib-cyclophosphamidedexamethasone (VCd): An analysis from the ANZ MRDR (Oral)

Sueh-li Lim, Cameron Wellard, Rajeev Rajagopal, Emma-Jane McDonald, Simon Harrison, Hang Quach, P Joy Ho, Erica Wood, Zoe McQuilten, Andrew Spencer

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis (Oral)

Betty Gration, Cameron Wellard, Elizabeth Moore, Marianne Tan, James Rowland, Michael Murphy, Kenneth Lim, Nada Hamad, Rajeev Rajagopal, Peter Mollee, Andrew Spencer, Hang Quach, Georgia McCaughan More efficient delivery of High-cost standard-of-care Therapies in Relapsed Multiple Myeloma using real-time feedback of Patient-reported outcome measures: the MY-PROMPT-2 trial (Oral)

Elizabeth Moore, Claudia Rutherford, John Reynolds, P Joy Ho, Zoe McQuilten, Elizabeth Moore, Tracy King, Erica Wood, Simon Harrison, Adam Irving, Andrew Spencer

The EpiMAP Myeloma model: A new tool for predicting the impact of changes to the Multiple Myeloma treatment pathway (Oral)

Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Kim Huynh, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer, Zoe McQuilten

Co-occurrence of Obesity and Diabetes adversely impacts overall survival (OS) in Multiple Myeloma (MM) – an analysis from the Australian and New Zealand Myeloma & Related Disease Registry (ANZ MRDR) (Oral)

Sabine Ringkowski, Angelina Yong, Matthew Wheeler, Anup George, Silvia Ling, Michael Low, Zoe McQuilten, Luke Merriman, Elizabeth Moore, Ruth Spearing, Nicholas Weber, Cameron Wellard, Hang Quach, Andrew Spencer, Soji Swaraj, Judith Trotman, Adam Bryant

Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma: a report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR) (Oral)

Betty Gration, Cameron Wellard, Elizabeth Moore, Peter Mollee, Andrew Spencer, Anita Shetty, Bart Baker, Cecily Forsyth, Jessica Heenan, Ian Kerridge, Zoe McQuilten, Erica Wood, Georgia McCaughan

Biallelic deletion of 1p32 in newly-diagnosed Multiple Myeloma (NDMM) patients associated with inferior outcomes: a report from the Myeloma and Related Diseases Registry (MRDR) (Poster)

Kenneth Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Adam Bryant, Georgia McCaughan, Sabine Ringkowski, Slavisa Ninkovic, Andrew Spencer, Hang Quach

National Myeloma Workshop August 2024, Melbourne

The Myeloma and Related Diseases Registry (MRDR) (Oral)

Andrew Spencer

Supporting real world research in myeloma: the 'data spine' of the Australian and New Zealand Myeloma and Related Disease Registry (Poster)

Elizabeth Moore, Erica Wood, Zoe McQuilten, Cameron Wellard, Andrew Spencer

New Zealand Myeloma Summit August 2024, Queenstown

Real world comparison of treatment outcomes for myeloma in elderly transplant ineligible population with RVD, Rd and VCD in frontline setting: Results from MRDR Australia and New Zealand, on behalf of MRDR investigators (Oral)

Sarah Zhao, Cameron Wellard, Elizabeth Moore, Peter Mollee, Hang Quach, Emma-Jane McDonald, Simon Harrison, P Joy Ho, Erica Wood, Zoe McQuilten, Andrew Spencer, Rajeev Rajagopal

PARTICIPATION & ENGAGEMENT

The MRDR supports site research staff who enter data, as well as researchers throughout the entire process of producing and publishing research outputs.

Data Manager Meetings

These six-monthly meetings provide:

- Education through expert guest speakers in areas relevant to data entry.
- Opportunity for site research staff to discuss issues arising, share expertise, and clarify definitions to enhance data quality.
- Feedback to sites on common errors, and tips to improve data collection processes.



ANZ MRDR Data Manager meeting, September 2024, Session 1

Research support for investigators

The MRDR works with researchers to provide advice and support with:

- Feasibility of your proposal
- Data analysis and interpretation
- Research design and methodology
- Ethics and governance advice for your project.



MRDR Data Manager, Dr Cameron Wellard, with researcher Roslyn Cao

Presentations at key national & international meetings

The MRDR is well represented at key national and international meetings and its data are sought after for many local and increasing international collaborations (see page 10).



ANZ MRDR presence in posters at ASH. Left, Ken Lim and Right, Georgia McCaughan, Andrew Spencer and Betty Gration

MRDR Annual Open Breakfast Meeting at Blood

This annual open meeting brings together site staff, investigators, researchers, industry partners, patient support and advocacy groups, and government representatives to:

- Learn about the latest MRDR data and research developments
- Attend the first public presentations of recent registry analyses
- Network within the ANZ Myeloma research community.



Top: Networking before the meeting; Bottom L to R: Chair and speakers; Questions from audience; Some MRDR team members and Principal Investigators

MRDR SITES AND PRINCIPAL INVESTIGATORS

Ashford Cancer Centre: Stanley Cheung Alfred Hospital: Andrew Spencer Auckland Hospital: Nicole Chien Austin Hospital: Jay Hocking Bairnsdale Regional Health Service: Amanda Ormerod Ballarat Hospital: Swe Htet Border Medical and Oncology: Anish Puliyayil Box Hill Hospital: Yee-Shuen Chong Cabrini Hospital: Gaurav Srivastava Calvary Mater Newcastle: Wojt Janowski Canberra Hospital: Maya Latimer (Acting) Central Coast Haematology: Cecily Forsyth Christchurch Hospital: Emma-Jane McDonald Concord Hospital: Nicole Wong Doo Cooks Hill Private Practice: Wojt Janowski Dunedin Hospital: Ian Morison Epworth Freemasons Hospital: Miles Prince Fiona Stanley Hospital: Stephanie Lam Flinders Medical Centre: TBC Frankston Hospital: Patricia Walker Geelong Hospital: Philip Campbell Griffith Hospital: Nada Hamad Hollywood Private Hospital: Bradley Augustson ICON Cancer Care: Ian Irving Latrobe Regional Hospital: Tricia Wright Launceston General Hospital: Jessica Heenan Lismore Hospital: Louise Imlay Liverpool Hospital: Adam Bryant Lyell McEwin Hospital: Stanley Cheung Middlemore Hospital: Rajeev Rajagopal Monash Medical Centre: Michael Low Nelson Hospital: Luke Merriman Nepean Cancer Centre: Anita Shetty Northern Hospital: Rachel Cooke North Shore Hospital: Anna Elinder-Camburn

Orange Health Service: Charmaine Wong Palmerston North Hospital: Bart Baker Peter Mac / Royal Melbourne: Amit Khot Princess Alexandra Hospital: Peter Mollee Royal Adelaide Hospital: Noemi Horvath Royal Brisbane & Women's Hospital: Nicholas Weber Royal Darwin Hospital: Tina Noutsos Royal Hobart Hospital: Sonali Sadawarte Royal North Shore Hospital: Ian Kerridge Royal Prince Alfred Hospital: P Joy Ho Sale: Central Gippsland Health: Amanda Ormerod Sir Charles Gairdner Hospital: Bradley Augustson St George Hospital: Sundra Ramanathan St Vincent's Hospital, Melbourne: Hang Quach St Vincent's Hospital, Sydney: Nada Hamad Sunshine Hospital: William Renwick Sunshine Coast University Hospital: Anthony Powell Tamworth Hospital: Israfil Baluwala Tauranga Hospital: Marie Hughes Toowoomba Hospital: Howard Mutsando Townsville Hospital: Andrew Birchley Wagga Wagga Hospital: Nada Hamad Wellington Hospital: Anup George Whangarei Hospital: Sarah Poplar

MRDR STUDENTS

Sueh-li Lim: Monash University, current PhD candidate

Krystal Bergin: Monash University, PhD completion 2022

Amanda Su: University of Melbourne, Master of Epidemiology, Research Project 2022

Daphne Antonopoulos: University of Melbourne, Master of Cancer Sciences, Research Project 2021

Rosalyn Cao: Monash University, Master of Public Health, Research Project 2019

Natthida Khajornjiraphan: Monash University, Master of Clinical Research Methods, Research Project 2019

Dervla O'Regan: Monash University, Master of Clinical Pharmacy, Research Project 2018



THANK YOU

The MRDR thanks participating individuals and sites, and our steering committee for all their work and contribution.

MRDR Steering Committee

Prof Andrew Spencer: Alfred Hospital / Monash University VIC

Dr Bradley Augustson: Sir Charles Gairdner Hospital WA

Dr Krystal Bergin: Alfred Hospital VIC

Prof Simon Harrison: Peter Mac / Royal Melbourne VIC

Prof P Joy Ho: Royal Prince Alfred Hospital NSW

Dr Tracy King: Royal Prince Alfred Hospital NSW

Prof Zoe McQuilten: Alfred Hospital / Monash University VIC

A/Prof Peter Mollee: Princess Alexandra Hospital QLD

Prof Hang Quach: St Vincent's Hospital, Melbourne VIC

Dr Rajeev Rajagopal: Middlemore Hospital, Auckland NZ

Mr Brian Rosengarten: Myeloma Australia

Prof Erica Wood: Monash University VIC Thank you to the following MRDR industry funding partners. We appreciate your support and look forward to a very productive 2025.







Ull Bristol Myers Squibb













sanofi



MRDR Management Committee

Coordinating Principal Investigator: Prof Andrew Spencer

Head of Transfusion Research Unit (TRU): **Prof Erica Wood**

Associate Investigator: **Prof Zoe McQuilten**

Research Fellow / ANZ MRDR Project Manager: **Dr Elizabeth Moore**

Data Manager: Dr Cameron Wellard

ANZ & APAC MRDR Research Officer: **Dr Tracy Zhang**

TRU Deputy Director – Operations: **Mr Neil Waters**

TRU Business Project Manager: Ms Naomi Aoki

TRU Registries Project Manager: Ms Vanessa Fox

Senior Data Officer: Dr Yayehirad Melsew

Business Development Project Manager (AMaRC): **Mr Khoa Le**





















CONTACT THE MYELOMA AND RELATED DISEASES REGISTRY (MRDR)

sphpm-myeloma@monash.edu 1800 811 326 mrdr.net.au

